Telomerase inhibitors and methods of use thereof
AssigneePresidents and Fellows of Harvard College
InventorsLourdes Gude-Rodriguez, Gregory L. Verdine, Shaunna Syu-Mei Stanton
Life of this patent
Estimating the term…
Abstract
One object of the present invention is to provide methods and compositions for inhibiting human telomerase, by providing inhibitors that bind to the CR4-CR5 or pseudoknot/template domains of the RNA component of human telomerase.
Claims30
A telomerase inhibitor, the telomerase inhibitor comprising a nucleic acid or analog thereof, which binds to the CR4-CR5 domain of the RNA component of human telomerase.
3-4. (canceled)
The telomerase inhibitor of claim, wherein said nucleic acid or analog thereof comprises a binding sequence length of 4-20 nucleotides.
(canceled)
A method of inhibiting telomerase activity, the method comprising contacting a telomerase with a nucleic acid or analog thereof, which binds to the CR4-CR5 domain of the RNA component of human telomerase.
11-12. (canceled)
16-25. (canceled)
A method of treating a proliferative disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of a telomerase inhibitor, wherein said telomerase inhibitor comprises a nucleic acid or analog thereof, which binds to the CR4-CR5 domain of the RNA component of human telomerase.
28-29. (canceled)
33-34. (canceled)
36-42. (canceled)
A telomerase inhibitor, the inhibitor comprising a nucleic acid molecule or analog thereof, which binds to the pseudoknot/template domain of the RNA component of human telomerase, wherein said nucleic acid molecule or analog thereof comprises a binding sequence selected from the group consisting of SEQ ID NO:
- 11-SEQ. ID NO:
- 45.
(canceled)
A method of inhibiting telomerase activity in a cell, the method comprising contacting a cell with a ribonucleic acid molecule or analog thereof, which binds to the pseudoknot/template domain of the RNA component of human telomerase, wherein said ribonucleic acid molecule or analog thereof comprises a binding sequence selected from the group consisting of SEQ ID NO:
- 11-SEQ. ID NO:
- 45.
47-52. (canceled)
54-55. (canceled)
Dependencies are inferred from the claim text.